How to Reconstitute Thymosin Alpha-1
A laboratory guide to reconstituting Thymosin Alpha-1 (Tα1), covering the peptide's identifiers, its reported receptor interactions, and the research models in which its mechanisms have been studied.
Thymosin Alpha-1 (Tα1), also written thymalfasin and thymosin α-1, is a 28-amino-acid acetylated peptide derived from the thymus. It is classified as an immunomodulatory peptide hormone, and the literature describes it as a synthetic version of a naturally occurring thymic peptide. The evidence block for this page does not supply a sequence string, molecular formula, or molecular weight, so those identifiers are not stated here; researchers should confirm them against the certificate of analysis accompanying their specific lot.
The mechanistic work described in the evidence centres on Tα1 acting as a non-canonical ligand for the Hypocretin (Orexin) Receptor 1 (HCRTR1), a classical neuropeptide receptor on neurons [1].
Reconstitution itself is a bench procedure: the lyophilised peptide is brought into solution with a suitable solvent, typically bacteriostatic or sterile water, and handled according to the supplier's instructions and the laboratory's own protocols. Because the evidence block does not specify a solvent, concentration, or handling temperature for this compound, no such values are given below. What follows instead is a summary of the research literature, organised by the mechanism, tissue, or model in which Tα1 has been examined.
Research Studies
Thymosin Alpha-1 and HCRTR1-mediated suppression of neuronal necroptosis
Work in this area reported that Tα1 functions as a non-canonical ligand for HCRTR1 on neurons, and that this engagement shields neurons from cell death by suppressing the activity of Receptor-Interacting Protein Kinase 3 (RIPK3), described as a central executioner of necroptosis [1]. The authors framed the finding as a direct neuroprotective axis linking the thymus to the central nervous system, and characterised the immune-to-brain signalling they observed as previously underappreciated [1]. This is a mechanistic, cell- and animal-level line of work; it does not establish clinical outcomes in humans.
Thymosin Alpha-1 and T-cell differentiation in the context of thymic involution
A review of aging and Tα1 describes immune decline in aging as driven mainly by thymic involution, the age-related shrinkage of the thymus gland, which reduces T-cell production and is accompanied by chronic inflammation and greater susceptibility to age-related disease [3]. In that framing, Tα1 is described as a thymus-produced peptide hormone with immunomodulatory, anti-inflammatory, and antioxidant properties, reported to help restore immune function by stimulating T-cell differentiation, enhancing thymic output, and modulating dendritic cell and macrophage activity [3]. The same review states that preclinical and clinical studies show Tα1 can improve vaccine response in the elderly and mitigate immunosenescence [3].
Thymosin Alpha-1 and dendritic cell chaperoning of a TLR7 ligand
One study reported that chemotherapy-induced cancer cell apoptosis releases apoptotic bodies that are poorly immunogenic or immunosuppressive, a barrier to coadministered or second-line immunotherapy, and that circulating levels of Tα-1 were reduced in that setting [9]. The same work reported that Tα-1 restores chemotherapy-induced antitumor immunity by chaperoning a microRNA ligand of TLR7 in dendritic cells [9]. This is a mechanistic finding reported in the cited paper; it is not a statement about human treatment response.
Thymosin Alpha-1 combined with immune checkpoint inhibition in nasopharyngeal carcinoma
A case report described a patient with nasopharyngeal carcinoma who developed multisystem immune-related adverse events after treatment with the PD-1 inhibitor sintilimab in combination with Tα1 [2]. The reported presentation included high fever, rash, interstitial pulmonary edema, and multiple organ failure [2]. The authors discussed risks and management strategies for combining immune checkpoint inhibitors with immunomodulators, and highlighted the need for clinical vigilance against possible immune overactivation triggered by combination therapy [2]. This is a single case report and should be read as such.
Thymosin Alpha-1 as an intervention for immune-related adverse events
A registered trial notes that Tα-1 has shown clinical benefits in patients whose immune functions are severely compromised or ineffective, and proposes to explore whether Tα-1 could be used as a therapeutic option for the treatment of immune-related adverse events [4]. This is a study record describing an intended investigation, not a report of results.
Thymosin Alpha-1 combined with lenvatinib and sintilimab in unresectable hepatocellular carcinoma
A retrospective study set out to validate the efficacy and safety of thymosin α-1 combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma, in patients treated at a single hospital [10]. As a retrospective design, this work supports hypothesis generation rather than causal inference.
Thymosin Alpha-1 in recurrent implantation failure
A registered trial is evaluating the safety and efficacy of Tα1 as an adjunctive immunomodulatory therapy in women with unexplained recurrent implantation failure undergoing IVF/ICSI cycles [7]. This is a study record; no outcome data are reported in the evidence block.
Thymosin Alpha-1 in neoadjuvant esophageal cancer regimens
A prospective, single-arm, multicentre study conducted in China is enrolling patients with pathologically or cytologically confirmed resectable esophageal squamous cell carcinoma to explore the efficacy and safety of adebrelimab combined with thymalfasin and chemotherapy as neoadjuvant therapy [6]. The record describes a screening period, a treatment period including neoadjuvant therapy and surgery, and a follow-up period comprising safety and survival follow-up [6].
Thymosin Alpha-1 in peptide therapy reviews for endocrine and immune modulation
A review of peptide therapies in thyroid health notes that thyroid disorders, particularly autoimmune conditions such as Hashimoto's thyroiditis, are frequently associated with persistent systemic symptoms despite biochemical normalisation on standard hormone replacement, which has prompted investigation into adjunctive strategies targeting immune, metabolic, and neuroendocrine pathways [11]. Tα1 appears within that broader review context rather than as the subject of a dedicated trial in the evidence supplied here.
Comparison of evidence types across the cited records
| Record | Design | Population or model | What it reports |
|---|---|---|---|
| [1] | Mechanistic study | Neurons; thymus-to-CNS axis | Tα1 engages HCRTR1 and suppresses RIPK3-driven necroptosis |
| [2] | Case report | Nasopharyngeal carcinoma patient | Multisystem irAEs after sintilimab plus Tα1 |
| [3] | Review | Aging and immunosenescence | T-cell differentiation, thymic output, vaccine response in the elderly |
| [4] | Registered trial | Patients with irAEs secondary to ICIs | Proposed exploration of Tα-1 for irAE treatment |
| [6] | Prospective single-arm trial | Resectable esophageal squamous cell carcinoma | Adebrelimab plus thymalfasin plus chemotherapy as neoadjuvant therapy |
| [7] | Registered trial | Women with unexplained recurrent implantation failure | Tα1 as adjunctive immunomodulatory therapy in IVF/ICSI |
| [9] | Mechanistic study | Dendritic cells; chemotherapy model | Chaperoning of a microRNA ligand of TLR7 |
| [10] | Retrospective study | Unresectable hepatocellular carcinoma | Tα-1 with lenvatinib plus sintilimab |
| [11] | Review | Thyroid disorders | Adjunctive peptide strategies in endocrine and immune modulation |
Two further registered studies in the evidence block do not centre on Tα1 as the intervention under test and are noted here only for completeness: an AI-assisted subtyping-directed precision treatment study in acute aortic dissection [5], and a phase II study of spatially fractionated radiotherapy combined with a multi-agent strategy in soft tissue sarcoma [8]. Neither should be read as evidence about Tα1 itself.
If you are reading this for personal health reasons
Thymosin Alpha-1 sold through this catalogue is supplied for laboratory research use only. We do not provide dosing information, reconstitution instructions for personal use, or medical guidance of any kind. If you are considering this or any other compound for yourself, speak to a licensed clinician.
Sources
- [1] Thymosin Alpha-1 Provides Direct Neuroprotection by Engaging the Orexin Receptor HCRTR1 to Suppress Neuronal Necroptosis — https://pubmed.ncbi.nlm.nih.gov/42693587/
- [2] A Case Report of a Multisystemic Immune-Related Adverse Event Caused by Sintilimab in Combination With Thymosin Alpha-1 — https://europepmc.org/article/PMC/PMC12883329
- [3] Aging and Thymosin Alpha-1 — https://europepmc.org/article/PMC/PMC12692621
- [4] Thymosin Alpha-1 for irAE Secondary to ICIs — https://clinicaltrials.gov/study/NCT06178146
- [5] AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection — https://clinicaltrials.gov/study/NCT07382375
- [6] Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer — https://clinicaltrials.gov/study/NCT07780721
- [7] Thymosin-α1 for Recurrent Implantation Failure — https://clinicaltrials.gov/study/NCT07675980
- [8] A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With the PraG Strategy for the Treatment of Soft Tissue Sarcoma — https://clinicaltrials.gov/study/NCT07342322
- [9] Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells — https://pubmed.ncbi.nlm.nih.gov/42295795/
- [10] The efficacy and safety of thymosin alpha-1 combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a retrospective study — https://europepmc.org/article/PMC/PMC12015295
- [11] Peptide Therapies in Thyroid Health: Emerging Applications in Endocrine and Immune Modulation — https://pubmed.ncbi.nlm.nih.gov/42222211/